Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | BPTF | Q12830 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.34 |
| ▸ | TP53 | P04637 | 5/20 | 0.34 |
| ▸ | SDHB | P21912 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | HTT | P42858 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.34 |
| ▸ | STAT3 | P40763 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | STAT1 | P42224 | 2/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16608850 | 0.88 | LMNA (0.41) | LMNASMN1; SMN2NOS3NOS2BPTF | |
| SCHEMBL17995542 | 0.83 | LMNA (0.38) | LMNASMN1; SMN2NOS3NOS2ESR1 | |
| SCHEMBL9432383 | 0.83 | SMN1; SMN2 (0.70) | LMNASMN1; SMN2NPSR1TP53KMT2A | |
| SCHEMBL1179309 | 0.82 | HCAR2 (0.38) | LMNASMN1; SMN2BPTFNPSR1TP53 | |
| SCHEMBL1179434 | 0.77 | ALDH1A1 (0.47) | LMNASMN1; SMN2NPSR1TP53RAB9A | |
| SCHEMBL805467 | 0.75 | PARP1 (0.50) | LMNASMN1; SMN2NPSR1TP53KMT2A | |
| SCHEMBL5909762 | 0.74 | LMNA (0.32) | LMNASMN1; SMN2 | |
| SCHEMBL4444099 | 0.71 | GLP1R (0.43) | LMNASMN1; SMN2NOS3NOS2NPSR1 | |
| SCHEMBL7753780 | 0.71 | LMNA (0.52) | LMNASMN1; SMN2BPTFNPSR1TP53 | |
| SCHEMBL4446017 | 0.69 | LMNA (0.36) | LMNASMN1; SMN2NOS3NOS2BPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238685-B2 | Benzo-fused heterocycles as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-03 | — | — | US | disclosed |
| US-20050124605-A1 | Novel benzo-fused heterocycles as endothelin antagonisits | ACTELION PHARMACEUTICALS LTD. | 2005-06-09 | — | — | US | disclosed |
| WO-2003013545-A1 | NOVEL BENZO-FUSED HETEROCYCLES AS ENDOTHELIN ANTAGONISITS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124605-A1 | Novel benzo-fused heterocycles as endothelin antagonisits | EDNRA, EDNRB, ECE1 | LMNA 983/4885SMN1; SMN2 4160/4885NOS3 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.